PTTG1 and metastatic prostate carcinoma: Over expression of CDC20 may be a potential biomarker for prediction of biochemical recurrence after radical prostatectomy of clinically localized PCa.[29] The present study revealed that CDC20 and PTTG1 contribute more to migration, progression, and poorer prognoses in metastatic prostate cancer (mPCa) compared with PCa.